ইস্রায়েল - হিব্রু - Ministry of Health

astrazeneca (israel) ltd - quetiapine fumarate - טבליות עם שחרור נרחב - quetiapine fumarate 200 mg - quetiapine

ইস্রায়েল - হিব্রু - Ministry of Health

astrazeneca (israel) ltd - quetiapine fumarate - טבליות עם שחרור נרחב - quetiapine fumarate 300 mg - quetiapine

ইস্রায়েল - হিব্রু - Ministry of Health

astrazeneca (israel) ltd - quetiapine fumarate - טבליות עם שחרור נרחב - quetiapine fumarate 50 mg - quetiapine

ইস্রায়েল - হিব্রু - Ministry of Health

astrazeneca (israel) ltd - quetiapine as fumarate - טבליות בשחרור ממושך - quetiapine as fumarate 150 mg - quetiapine

ইস্রায়েল - হিব্রু - Ministry of Health

astrazeneca (israel) ltd - quetiapine fumarate - טבליות עם שחרור נרחב - quetiapine fumarate 400 mg - quetiapine

ইস্রায়েল - হিব্রু - Ministry of Health

astrazeneca (israel) ltd - selumetinib as hyd-sulfate - קפסולה קשיחה - selumetinib as hyd-sulfate 10 mg - selumetinib

ইস্রায়েল - হিব্রু - Ministry of Health

astrazeneca (israel) ltd - selumetinib as hyd-sulfate - קפסולה קשיחה - selumetinib as hyd-sulfate 25 mg - selumetinib

ইস্রায়েল - হিব্রু - Ministry of Health

astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.

ইস্রায়েল - হিব্রু - Ministry of Health

astrazeneca (israel) ltd - saxagliptin as hydrochloride - טבליות מצופות פילם - saxagliptin as hydrochloride 5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

ইস্রায়েল - হিব্রু - Ministry of Health

astrazeneca (israel) ltd - saxagliptin as hydrochloride - טבליות מצופות פילם - saxagliptin as hydrochloride 2.5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.